University Research

​大学合作类研发基金

NSERC Alliance COVID-19 Grant

In response to the COVID-19 pandemic, NSERC (Natural Sciences and Engineering research council of Canada) is leveraging the expertise of researchers in natural science and engineering and their partners across Canada to address this unprecedented crisis.

NSERC is providing up to $15 million in total support to stimulate collaborations between academic researchers and the public and not-for-profit sectors, and industry to address pandemic-related research and technical challenges. Support for up to $50,000 for one-year projects is being made available immediately.

为了应对新冠病毒大流行,NSERC (加拿大自然科学与工程研究理事会) 正在利用自然科学和工程研究人员及其合作伙伴在加拿大的研发能力来应对这一前所未有的危机。

NSERC提供了总计1500万加元的总资助,以促进学术研究人员与企业和非营利研究机构形成行业合作,以解决与大流行相关的研究和技术挑战。 基金为每一个立项项目提供为期一年高达50,000加元的研究经费支持。

Objectives:

  • accelerate the flow and exchange of research results and research expertise in the natural sciences and engineering sectors between academic researchers and public, not for profit and industry partners by supporting these organizations as they face challenges in relation to the COVID-19 pandemic;

  • support research and analysis activities that address partner organization questions or issues in relation to the COVID-19 pandemic, leading to applications in the short term.

  • 支持自然科学和工程技术领域的学术研究成果交流,加快产学合作,促进学者、行业专家、企业研发团队携手创新交流,共同解决疫情带来的挑战。

  • 支持合作伙伴企业或组织通过研究和分析将研究成果在短期内应用到实际解决疫情相关问题的项目中。

You can request up to $50,000 from NSERC. Cash contributions from partner organizations are not required.

Collaborating outside the natural sciences and engineering: Developing applications or policies based on your research results may require socio-economic and other expertise in addition to scientific understanding. You are encouraged to collaborate with academic researchers in fields other than the natural sciences and engineering. Such researchers may serve as co-applicants for these grants. Research costs for these collaborations must be identified in the project budget, up to a maximum of 30% of the cost-shared project costs.

一个立项项目最多申请$ 50,000加元。 不要求企业合作伙伴必须投入现金支持。

允许与人文社会科学领域学者共同合作:与研究课题相关的社会科学领域的研究人员可以作为项目共同申请人。 这些合作的研究费用必须在项目预算中确定,最多不得超过项目费用的30%。

Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding

On March 19, 2020, the honourable Patty Hajdu, Canada’s Minister of Health, announced an additional investment of $25.8M to the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research competition. This additional funding is a portion of the $275M dedicated for COVID-19 research as announced by the Prime Minister on March 11, 2020. With this investment, CIHR will be able to fund an additional 49 grants, which brings the total number of grants funded to 96 and a total investment of $52.6M

 

2020年3月19日,加拿大卫生部长(Patty Hajdu)宣布,将向加拿大2019年新型冠状病毒(COVID-19)快速研究基金追加投资2580万加元。 这笔额外的资金是总理于2020年3月11日宣布的2.75亿加元专用于COVID-19研究的一部分。通过此项投资,CIHR将能够再资助49个研究项目,总研发经费投入达到5260万加元。

The COVID-19 Challenges Procurement Program: 

NRC Industrial Research Assistance Program and Innovative Solutions Canada

This program will post challenges seeking near-to-market solutions from small and medium-sized businesses (fewer than 500 staff) that need financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to refine and sell their product or solution to meet a COVID-19 related need.

该计划将发布挑战,以寻求需要加拿大国家研究委员会工业研究援助计划(NRC IRAP)财政支持的中小企业(少于500名员工)的符合当前疫情要求的解决方案。

NRC IRAP will partner with Innovative Solutions Canada to launch calls for proposals over the next few weeks to address challenges, fund development of solutions, and buy successful products and services needed to address COVID-19.
Together, NRC IRAP and Innovative Solutions Canada will:
Post the PHAC and HC challenges (Innovative Solutions Canada)
Award Phase 1 funding to successful small and medium-sized businesses to develop a proof of concept for their solution (NRC IRAP)
Award Phase 2 funding to the firms with the best concepts so they can develop a working prototype (NRC IRAP)
The NRC, PHAC, HC or another federal department or agency will then be able purchase the product for use against COVID-19.

NRC IRAP将与Innovation Solutions Canada合作,在接下来的几周内发起提案征集,以应对挑战,为解决方案的开发提供资金,并购买成功解决COVID-19所需的产品和服务。
NRC IRAP和加拿大创新解决方案将共同努力:
发布PHAC和HC挑战(加拿大创新解决方案)
向成功的中小企业授予第一阶段资金,以进行概念证明(NRC IRAP)
向具有最佳概念的公司授予第二阶段的资金,以便他们可以开发工作原型(NRC IRAP)
然后,NRC,PHAC,HC或其他联邦部门或机构将能够购买针对COVID-19开发的产品。

The Pandemic Response Challenge Program:

National Research Council of Canada

This program will build teams to address challenges requiring further research and development for solutions to meet COVID-19 related needs. 

该计划将组建团队来应对需要进一步研发解决方案的挑战,以满足与COVID-19相关的需求。

The NRC will receive $15M to form dedicated teams to address challenges in the areas of greatest research and development (R&D) need in the fight against COVID-19. The NRC Pandemic Response Challenge Program will accelerate the development of diagnostics and medical countermeasures for a rapid front-line response to protect and treat Canadians. This national vehicle will convene the best Canadian and international researchers from academia and small and medium-sized businesses to collectively accelerate R&D to address specific COVID-19 gaps and challenges as identified by Canadian health experts. The Pandemic Response Challenge Program is currently structured around 3 main research areas:

  • Rapid detection and diagnosis

  • Therapeutics and vaccine development and

  • Digital health

NRC将获得1500万加元的资金,组成专门团队应对COVID-19带来的研究开发的挑战。 NRC Pandemic Response Challenge Program将加快诊断和医学对策的开发,以迅速采取一线应对措施来保护和治疗加拿大人。 该研究基金将召集来自学术界和中小企业研究精英人才,共同加快研发速度,以解决加拿大卫生专家确定的特定COVID-19挑战。该研究基金3个主要研究领域:

  • 快速检测和诊断

  • 治疗和疫苗开发以及

  • 数字健康

Biomanufacturing capacity at Royalmount:

NRC Human Health Therapeutics Research Centre

This initiative will result in a Good Manufacturing Practices platform to develop and scale up COVID-19 Canadian vaccine and therapy candidates.

该计划将建立一个良好生产规范平台,以开发和扩大生产COVID-19加拿大疫苗和治疗候选药物。

The NRC Biomanufacturing facility, located in the NRC's Royalmount Avenue building in Montréal, is used to develop and scale up processes to produce biological medicines and is managed by the Human Health Therapeutics Research Centre. As part of its development capacity, the facility is equipped with pilot-scale bioreactors (200 L and 500 L), which will be operationally available to produce up to 100,000 doses of vaccine per month within 6 months once a vaccine suitable for front-line responders is available.

A $15 million investment will fund the certification of the facility for Good Manufacturing Practices compliance, and will enable production of material that will be used in humans, particularly for vaccines or therapeutics. This certification can also greatly increase the capacity for candidate vaccines or therapeutics to be quickly rolled out and clinically tested, particularly those originating from Canada. The work to refine and certify quality systems at the facility will include: bringing the existing facility to regulatory standards, installing equipment to expand capacity, and managing information.

Once certified, this facility will be able to accelerate the scale-up production and testing of various types of vaccine candidates in the context of the current COVID-19 outbreak, including protein-based, viral vector-based, and antibody-based products.

NRC生物制造设施位于NRC蒙特利尔的Royalmount Avenue大楼内,用于开发和扩大生产生物药品的流程,由Human Health Therapeutics Research Centre管理。作为其开发能力的一部分,该设施配备了中试规模的生物反应器(200升和500升),一旦适合一线使用的疫苗,将可在6个月内生产多达100,000剂疫苗/月。

1500万加元的投资将为设施的良好制造规范合规性认证提供资金。该认证还可以极大地提高候选疫苗或治疗剂(尤其是来自加拿大的疫苗或治疗剂)的快速推出和临床测试能力、完善和认证设施质量体系等。

一旦获得认证,该基金可以加速大规模生产和测试各种类型的候选疫苗,包括基于蛋白质,基于病毒载体和基于抗体的产品。
 

Operating Grant : COVID-19 Clinical Epidemiology Research Rapid Response (Application Closed)

CIHR and partner(s) financial contributions for this initiative are subject to availability of funds. Should CIHR or partner(s) funding levels not be available or are decreased due to unforeseen circumstances, CIHR and partner(s) reserve the right to reduce, defer or suspend financial contributions to the grant received as a result of this funding opportunity.

The total amount available for this funding opportunity is $1,000,000, enough to fund one grant for up to one year.
 

此政府资助的研究项目最高金额为$ 1,000,000,为期最多一年。

Ontario's Action Plan: Responding to COVID-19

$3.7 billion to support people and jobs: Helping to support regions lagging in employment growth with a proposed new Corporate Income Tax credit — the Regional Opportunities Investment Tax Credit; 

37亿加元用于支持人员和工作:包括拟议的新企业所得税抵免 - 投资税务抵免

 

© 2020 by LYNDEX TECHNOLOGY